In combination with the PARP inhibitor olaparib, SBP-7455 synergistically kills MDA-MB-468 TNBC cells, displaying a more effective mode of action through PARP and autophagy inhibition to kill tumour cells than either mechanism alone [147]. Here, PARP1 is linked to neoplasm.